2D-radiotherapy in Palliation of Advanced Esophageal Cancer
SHARON-2D
Short-course Accelerated 2D-radiotherapy in Palliative Treatment of Advanced Esophageal Cancer
1 other identifier
interventional
17
0 countries
N/A
Brief Summary
The study wants to define the efficacy of a short course 2D-radiation therapy in patients with symptomatic advanced esophageal cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2009
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
April 17, 2019
CompletedFirst Posted
Study publicly available on registry
April 19, 2019
CompletedSeptember 16, 2019
September 1, 2019
10 years
April 17, 2019
September 12, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of symptoms [odynophagia, chest-back pain, dysphagia, regurgitation]
Symptoms were graded using the IAEA scoring system. Values range from 0 (no symptom) to 4 (severe symptom).
1 year
Secondary Outcomes (3)
Incidence of Treatment-Emergent Adverse Events [Acute radiation toxicity]
1 year
Assessment of the Performance Status
1 year
Assessment of the Overall Survival
1 year
Study Arms (1)
Short course radiotherapy
EXPERIMENTALThe radiotherapy is delivered over 2 days with accelerated hypo-fractionation and 2D-technique.
Interventions
An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
Eligibility Criteria
You may qualify if:
- histologically proven advanced esophageal cancer
- excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status
- age \> 18 years
- Eastern Cooperative Oncology Group (ECOG) \<3
You may not qualify if:
- prior radiotherapy to the same region
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alessio G. Morganti, MD
Radiation Oncology Center, DIMES, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 17, 2019
First Posted
April 19, 2019
Study Start
January 1, 2009
Primary Completion
January 1, 2019
Study Completion
January 1, 2019
Last Updated
September 16, 2019
Record last verified: 2019-09